Mounjaro vs Compounded Tirzepatide
Mounjaro is the FDA-approved branded tirzepatide pen for type 2 diabetes. Compounded tirzepatide is prepared by a licensed pharmacy under provider review for metabolic optimization when supply or titration requires it.
Branded Mounjaro is appropriate where insurance and FDA-labeled diabetes indication align.
Compounded tirzepatide is appropriate for provider-reviewed metabolic optimization with tuned titration.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Is compounded tirzepatide regulated?
Yes — by state boards of pharmacy and the FDA under 503A/503B pathways.
What changes when supply normalizes?
Pathway availability of compounded formulations may evolve; candidacy decisions remain provider-reviewed.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment